Jefferies Financial Group Inc. Makes New $251,000 Investment in Delcath Systems, Inc. (NASDAQ:DCTH)

Jefferies Financial Group Inc. bought a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 20,806 shares of the company's stock, valued at approximately $251,000. Jefferies Financial Group Inc. owned approximately 0.07% of Delcath Systems at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Baader Bank Aktiengesellschaft purchased a new stake in shares of Delcath Systems during the fourth quarter valued at $204,000. Principal Financial Group Inc. raised its stake in shares of Delcath Systems by 28.8% in the fourth quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock worth $1,387,000 after purchasing an additional 25,736 shares during the last quarter. Private Advisor Group LLC purchased a new stake in Delcath Systems in the fourth quarter valued at approximately $153,000. Charles Schwab Investment Management Inc. acquired a new position in Delcath Systems during the fourth quarter valued at $156,000. Finally, Quantbot Technologies LP purchased a new position in shares of Delcath Systems in the 4th quarter valued at about $66,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Wall Street Zen lowered shares of Delcath Systems from a "strong-buy" rating to a "buy" rating in a report on Sunday. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price target (up from $24.00) on shares of Delcath Systems in a research note on Friday, May 23rd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $24.00.

Delcath Systems Stock Performance

Shares of NASDAQ DCTH traded up $0.30 during mid-day trading on Wednesday, reaching $16.38. The company's stock had a trading volume of 331,353 shares, compared to its average volume of 379,367. The stock has a 50-day moving average of $13.48 and a two-hundred day moving average of $13.31. The stock has a market capitalization of $570.45 million, a P/E ratio of -12.13 and a beta of 0.95. Delcath Systems, Inc. has a 1-year low of $6.42 and a 1-year high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). The business had revenue of $19.80 million during the quarter, compared to analysts' expectations of $16.83 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. Analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.